Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Natglycan, LLC
- Proposal award date
- 2019-03-01
- Contract end date
- 2021-02-28
- UEI
- NMMMHXNPL8U5
- Solicitation number
- PA16-157
- Topic code
- 300
Research abstract
In addition to essential nutrients and bioactive antibodies, human milk is unique in providing a rich pool of free-
reducing human milk glycans (HMG) that are minimally digested in the upper GI tract and transported intact into
the lower intestine, where, they have well-known pre- and probiotic effects and interfere with pathogen
attachment by acting as soluble decoy receptors. HMGs also appear in the circulation, suggesting they
participate systemically in physiological processes. HMGs may enhance the epithelial barrier function of the gut
and regulate neuronal dependent gut motility and perhaps enhancement of cognition via the gut-brain axis.
Benefits of breastfeeding stimulated manufacturers of nutritionals to develop supplements to infant formula that
provide the beneficial effects of motherandapos;s milk. Abbott Nutrition and Nestle Nutrition recently introduced infant
formula containing LNnT and/or 2andapos;-FL. These HMG are now commodities manufactured as supplements using
fermentation process to supply a global market. Although HMG are beneficial to infants, we know little about the
biological mechanisms of any of the hundreds of HMG. A primary function of glycans in living organisms is their
specific recognition by glycan binding proteins (GBPs), and protein-glycan interactions have been investigated
for many years. Currently the most effective technology for investigating protein-glycan interactions is the printed
glycan microarray where glycans are attached to a glass microscope slides and interrogated with GBP to
discover and characterize protein-glycan interactions. We have discovered several potentially important
interactions of viruses, antibodies, galectins and DC-SIGN using the first HMG glycan microarrays, believe that
these discovery platforms can reveal therapeutically relevant protein-glycan interactions. Using our HMG glycan
array with the glycan binding domain (VP8*) of rotavirus adhesins, we discovered, for the first time, several
glycan determinants that may function as anti-adhesins, and the HMG structures carrying these determinants
had never been identified in spite of 60 years of study on the structure of HMG. These studies led us to look at
HMG as a subset of the larger human glycome. We developed a method to predict what structures make up
HMG glycome, compiled these structures in a database that we can use for a new approach to glycan
sequencing that could be a model for the more monumental task of sequencing the larger human glycome.
Having constructed 2 version of an HMG glycan microarray, we know the difficulties of constructing and
maintaining the required glycan libraries in an academic setting, and here we propose a commercial solution
using large-scale processes developed by NatGlycan to build a sustainable HMG library of pure structures and
construct a comprehensive array of completely defined glycans that represent the complete HMG glycome,
which will be a discovery, screening platform for relevant protein-glycan interactions for use by pharmaceutical
companies seeking glycan based drugs.Manufacturers of infant formulas currently supplement their products with one or two Human Milk Glycans
(HMG) to make them more like motherandapos;s milk, hoping to provide the well-known benefits of HMG to breastfed
infants. Although HMG are very important in normal physiology, much is yet to be learned about the
physiological mechanisms of any individual HMG among hundreds in milk. NatGlycan proposes to use its
proprietary method for extracting natural glycans to produce the full array of HMGs at a commercial scale to
support the academic and pharmaceutical research industry in discovering and characterizing physiologically
relevant protein-glycan interactions.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
5 SBIR/STTR records share this UEI (2017–2022). Reported award amounts total $3,060,733. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards